• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Therapeutic Vaccine Shows Potential in Fighting Cervical Cancer


In a small, preliminary study, an experimental vaccine provoked a strong immune response against precancerous cells in women treated for cervical lesions that can progress to cancer.

Most cases of cervical cancer are caused by infection with two types of human papillomavirus, or HPV. Some women who have precancerous cervical lesions associated with the Type 16 and Type 18 strains of HPV are able to fight them off without medical intervention. They do so by producing high levels of immune cells called killer T-cells.

Read the full story: http://nyti.ms/SQVgeX

Source: The New York Times

Related Videos
Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions
dr kimberly maxfield
Amal Trivedi, MD
dr amy laughlin
dr kathi mooney
dr saira jan
dr saira jan
Ted Okon, MBA, Community Oncology Alliance
Miriam J. Atkins, MD, FACP, Community Oncology Alliance/AO Multispecialty Clinic
Related Content
© 2023 MJH Life Sciences
All rights reserved.